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Boric acid (BA) is a naturally occurring agent used in manufacturing processes and numerous consumer products. Because of the potential for both
industrial and consumer exposure to boron-containing compounds, and the lack of developmental toxicity data, the National Toxicology Program
evaluated the potential for boric acid to cause developmental toxicity in pregnant Swiss (CD-1) mice, Sprague-Dawley rats (n = 26-28/group), and
New Zealand rabbits (n = 18-23/group). BA was provided in the feed to mice and rats at 0, 0.1, 0.2, or 0.4% throughout gestation to attain steady-
state exposure as early as possible during development. Average doses (mg/kg/day) were 248, 452, or 1003 for mice, and 78, 163, or 330 in rats.
A separate group of rats received 0.8% BA in the feed, or 539 mg/kg/day only on gestation days (gd) 6 to 15. Rabbits were given BA (0, 62.5, 125,
or 250 mg/kg) by gavage administration on gd 6 to 19. Maternal body weight, food and/or water consumption and signs of toxicity were monitored
at regular intervals. At termination, gd 17 (mice), 20 (rats), or 30 (rabbits), the uterus was examined to determine the number of resorptions, dead, or
live fetuses. Fetuses were weighed and live fetuses were examined for external, visceral, and skeletal defects. Mouse dams exhibited mild renal
lesions (.248 mg/kg/day BA), increased water intake and relative kidney weight (1003 mg/kg/day BA), and decreased weight gain during treat-
ment. Maternal rats exhibited increased liver and kidney weights at 2163 mg/kg/day BA, altered water and/or food intake at >163 mg/kg/day BA,
and decreased weight gain at >330 mg/kg/day BA. In rabbits, signs of toxicity included decreased food consumption during treatment, and vaginal
bleeding associated with pregnancy loss at 250 mg/kg/day. Maternal body weight (gd 9 to 30), weight gain during treatment, and gravid uterine
weight decreased at 250 mg/kg/day. Relative maternal kidney weight (but not absolute weight) was increased at 250 mg/kg/day, but microscopic
evaluation did not indicate any renal pathology associated with BA exposure. BA is a developmental toxicant in all three species. The lowest-
observed-adverse-effect level (LOAEL) for developmental toxicity was 78 mg/kg/day for rats (fetal weight reduction), 250 mg/kg/day for rabbits
(prenatal mortality and malformations), and 452 mg/kg/day for mice (fetal weight reduction). The no-observed-adverse-effect levels (NOAELs) for
developmental toxicity in these species were <78 mg/kg/day (rats), 125 mg/kg/day (rabbits), and 248 mg/kg/day (mice). With regard to maternal
toxicity, the rat was the most sensitive (163 mg/kg/day), while both the mouse and rabbit showed maternal toxicity at 250 mg/kg/day. Thus,
developmental toxicity occurred below maternally toxic levels in the rat, and only in the presence of maternal toxicity in mice or rabbits. - Environ
Health Perspect 102(Suppl 7):107-112 (1994)
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Introduction
Boric acid is a naturally occurring agent
used in manufacturing processes and
numerous consumer products (1-3). At
high concentrations, boric acid is a repro-
ductive toxicant in mice (4) and rats (5-7).
While males appear to be the predominandy
affected sex (4), other investigators have
shown that pregnancy in mice can also be
disrupted by boric acid exposure. A single
dose of boric acid (500-3000 mg/kg) to
mice on the first day of pregnancy disrupted
pregnancy because of failure of blastulation
in mice (2). There is also evidence that
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boric acid decreased ovulation in rats (3).
Teratogenic effects such as rumplessness
and microphthalmia have been reported in
chick embryos treated with boric acid
(8,9). There has been a report ofincreased
malformations (especially congenital
cataracts) among children of pregnant
women who used boric acid as a topical
antimicrobial agent (10).
Because of the high industrial produc-
tion ofboric acid, the potential for human
exposure to products containing boric acid,
and data indicating the reproductive toxici-
ty and possible developmental toxicity of
boric acid, the National Toxicology
Program (NTP) designed studies to define
the potential for boric acid to cause devel-
opmental toxicity in mice, rats, and rabbits.
This was accomplished in studies in which
the females were dosed orally with boric
acid shortly after mating and continued
until the day prior to natural parturition,
or during any specific periods within this
time frame. Both maternal and develop-
mental toxicity end points were evaluated.
Detailed reports of these studies are avail-
able (11-13) and the studies in mice and
rats have been published (14). A summary
of the results of these three studies is pre-
sented here.
Materials and Methods
Chemical Boric acid (CAS no. 10043-35-
3) was determined to be 99% pure by
infrared spectroscopy.
Animals and Husbandry. Adult
Caesarean-originated, barrier-sustained
Crl:CD-1 (ICR) VAF/Plus outbred Swiss
albino (CD-1) mice (Charles River
Laboratories, Portage, MI); Crl:CD BR
VAF/Plus outbred Sprague-Dawley (CD)
rats (Charles River Laboratories, Raleigh,
NC); and New Zealand rabbits (Hazelton
Research Products, Denver, PA) were used
for these studies (Table 1).
Treatment. Time-mated rats or mice
were given boric acid in the feed continu-
ously from the morning of gestation day
(gd) 0 to the morning ofgd 20 (rats) or gd
17 (mice) at doses of0, 0.1, 0.2, or 0.4%,
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Table 1. Specific protocol.
Species Sprague-Dawley rat Swiss CD 1 mice NewZealand rabbit
No. dams/group 26-28 26-28 18-23
Mode of exposure Feed Feed Gavage
Dosing interval gd 0-20 (gd 6-15) gd 0-17 gd 6-19
Concentration in feed 0, 0.1, 0.2, 0.4, (0.8%) 0, 0.1, 0.2, 0.4%
Dose/unit body weight 0, 78, 163, 330, 538 mg/kg/day 0, 248, 452, 1003 mg/kg/day 0, 62.5, 125, 250 mg/kg/day
Termination gd 20 gd 17 gd 30
or from gd 6 through 15 (0.8% dose, rats
only). Rabbits were artificially inseminated
(15,16) and given boric acid by gavage
(62.5, 125, or 250 mg/kg/day in distilled
water) on gd 6 through 19 (Table 1).
Administration ofboric acid by gavage was
chosen for the rabbit study because rabbits
are erratic eaters.
Evaluations. End points used to define
maternal toxicity during boric acid treat-
ment included food and water consump-
tion, body weight, signs of toxicity, liver
and kidney weights, kidney histology, and
uterine weight. Animals were killed on gd
17 (mice), gd 20 (rats), or gd 30 (rabbits).
End Points. End points used to define
developmental toxicitywereembryonal/fetal
weight and structural malformations and
variations observed during examinations.
Live fetuses were weighed and examined
for malformations and variations by stan-
dard techniques (17-20).
Statistics. Statistical analysis of the data
was made as described previously, using the
litter as the statistical unit (11-14).
Results
Rau
Maternal Effects. Summarizing across all
exposure groups, maternal effects included
increased relative liver and kidney weights
at .0.2%, and decreased weight gain dur-
ing treatment and gestation at .0.4%.
Corrected body weight gain (i.e., gesta-
tional weight gain minus the gravid uter-
ine weight) was not affected, except for a
significant increase when compared to the
control group at 0.4% boric acid (Table
1). Microscopic evaluation of maternal
kidney sections showed minimal
nephropathy in a few rats, but neither the
incidence nor the severity of the changes
was dose related. Exposure to boric acid
from gd 0 to 20 resulted in increased food
intake with no significant dose-related
effect on water intake. Exposure to 0.8%
boric acid resulted in decreased water and
food intake early during the treatment
period with a rebound increase in food
intake on gd 15 to 18 and an apparent,
but not significant, increase in water
intake over this same period.
Embryonal/Fetal Effects. Prenatal mor-
tality was significantly increased in the
0.8% dose group (36% resorptions per lit-
ter) relative to the control group (4%
resorptions per litter) that resulted in a
decrease in live litter size. Significant
increases in both the percentage of
embryonic loss (resorptions) and late fetal
deaths per litter contributed to the
observed increase in prenatal mortality
after exposure on gd 6 to 15. Average
fetal body weight per litter was also
reduced in all boric acid-treated groups,
ranging from a 6 to 7% decrease at the
lowest dose level to about a 50% decrease
at the highest dose level. The percentage
of malformed fetuses per litter and the
percentage of litters containing at least
one malformed fetus were increased at all
doses studied. The incidence of litters
with one or more fetuses with a skeletal
malformation increased at 0.2 to 0.8%
boric acid doses; the incidence of litters
with one or more pups with a visceral or
external malformation was increased at
dosages of 0.4 and 0.8%, respectively. A
variety of malformations was noted,
including anomalies of the eyes, the cen-
tral nervous system, the cardiovascular
system, and the axial skeleton. The most
commonly observed malformations in the
0.4 and 0.8% dosage groups were
Table 2. Summary of maternal andembryonal/fetal responses of Sprague-Dawley rats to boric acid administered
on gestational days 0to 20 or6 to 15.
Boric acid, mg/kg/day(% in feed)
0-20 6-15
78 163 330 539
Trend (0.1%) (0.2%) (0.4%) (0.8%)
Maternal
Total treated 29 29 29 14
Number removed 0 0 0 0
Deaths 0 0 0 0
Pregnancy rates, % 97 90 90 100
Bodyweight before treatment - - -
Bodyweight change during treatment 4. a I- ,j,,
Bodyweight change, corrected 1' - - T
Relative food consumption - - 1 4.
Clinical signs oftoxicity
Number corpora lutea/dam - - - - J1
Gravid uterine weight Jl - - 4. 4
Relative liverweight 1
Relative kidney weight I -
Renal pathology
Embryonal/fetal
% resorptions orfetal deaths/litter - - - - 1
% litters with resorptions ordeaths - - - - 1
% litterswith 100% prenatal mortality - - - - T
Number live fetuses/litter - - - - 4
Average female bodyweight/litter 4. 4 4. 4 4.
Average male bodyweight/litter 4. 4 4. 4 4.
% malformed fetuses/litter T - II 1
% litters with malformations
All T - TI T
External - - - - t
Visceral - - - T I
Skeletal T 1 1 1t
% fetuses with variations/litter - 4 4 - T
% litters with variations - 4 4. - -
a Arrows indicate direction of the trend or significant change from the control group (p<0.05). b Dashes indicate
no significant change from control.
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enlarged lateral ventricles of the brain (0
and 0.5% of the fetuses, respectively),
and agenesis or shortening of the thir-
teenth rib (6 and 45% of the fetuses,
respectively) (Table 2).
Mice
MaternalEffects. Maternal toxicity associat-
edwith boric acid treatment induded effects
on body weight gain and organ weights.
Maternal body weight was reduced below
control values by 10 to 15% during late
treatment in the high-dose group.
Treatment with 0.4% boric acid also caused
reductions in maternal weight gain during
treatment, but weight gain corrected for
uterine weight was not affected. Food and
water intake were not affected. Gravid uter-
ine weight was decreased at the high-dose
level. At necropsy, pale kidneys were noted
in several boric acid-treated dams, particu-
larly in the high-dose group, and one dam
treated with 0.4% boric acid had fluid accu-
mulation in the kidney. Relative kidney
weight was increased in the 0.4% group and
microscopic examination of maternal kid-
neys revealed a dose-related increase in the
incidence ofrenal tubular dilatation (with or
without regeneration), 0/ 10, 2/ 10, 8/10
and 10/10; control to high-dose group,
respectively.
Embryonal/Fetal Effects. boric acid
treatment (0.1-0.4%) during gestation was
not associated with preimplantation loss, the
number ofimplantation sites per litter being
comparable among treatment groups (Table
3). However, boric acid treatment was asso-
ciated with significant adverse postimplanta-
tion effects, particularly in the high-dose
group. The percentage ofresorptions per lit-
ter increased from 6% in the control group
to 19% by exposure to 0.4% boric acid, and
fetal bodyweight was reduced by 33% com-
pared to controls. Treatment with 0.2%
boric acid was also associated with a signifi-
cant, but less severe, fetal body weight
reduction of11%.
Boric acid also had effects on fetal mor-
phologic development. The most frequent-
ly observed malformations in the 0.4%
boric acid-treated litters were skeletal
defects, particularly short rib XIII (in the
4% dosage-treated fetuses). In contrast, the
occurrences of fetuses per litter with mal-
formations were fewer in the low- and mid-
dose group than in the control group. In
particular, the incidence of full or rudi-
mentary lumbar I rib(s) was observed less
frequently in fetuses of boric acid-treated
mice. The presence of a rib at lumbar I
(classified as an anatomic variation in this
species and strain) was decreased in a dose-
Table 3. Summary of maternal and embryonal/fetal responses of CD-1 mice to boric acid administered on gesta-
tional days 0 to 17.
Boric acid, mg/kg/day(% in feed)
248 452 1003
Trend (0.1%) (0.2%) (0.4%)
Maternal
Total treated 28 29 28
Number removed 0 0 0
Deaths 0 0 0
Pregnancy rates, % 96 93 93
Bodyweight before treatment
Bodyweight change during treatment(gd 0-17) 4-a _ - 4
Bodyweight change (corrected)
Relative food consumption )gd 0-17) - - -
Clinical signs oftoxicity
Number corpora lutea/dam
Gravid uterine weight '1 - - 4-
Relative liverweight 4, - - 4-
Relative kidneyweight 1 - - 1
Renal pathology I 1T
Embryonal /fetal
% resorptions orfetal deaths/litter 1
% litters with resorptions or deaths - - -
% litters with 100% prenatal mortality
Number livefetuses/litter
Average female bodyweight/litter 4- - ,l,
Average male bodyweight/litter 4- - 1-
% malformed fetuses/litter I - - I





% fetuses with variations/litter - 4- 4-
% litters with variations - 4, 4-
a Arrow indicate direction of the trend or significant change from the control group)p<0.05). b Dashes indicate no
significant changefrom control.
related manner as follows: the incidence of
a full rib(s) at lumbar I was 12, 8, 1, and
1%, respectively, and the incidence ofrudi-
mentary lumbar I rib(s) was 16, 7, 3, and
3%, respectively.
Rabbits
Maternal Effects. At 250 mg/kg/day,
maternal food consumption was decreased
during the first 10 days of treatment (gd
6-15), was comparable among groups
during the final days of treatment (gd
15-19), and was increased during the peri-
od immediately following treatment (gd
19-25). It was also increased in both the
125 and 250 mg/kg/day groups relative
to controls during the final days of gesta-
tion (gd 25-30). Maternal body weight
(gd 9-30), weight during treatment, and
gravid uterine weight were each decreased
at 250 mg/kg/day. Corrected maternal
weight change was increased at both 125
and 250 mg/kg/day. Maternal relative
liver weight was comparable among
groups, while relative kidney weight was
increased at 250 mg/kg/day. However,
there was no histopathologic evidence for
any boric acid-induced renal toxicity.
Embryonal/Fetal Effects. No definitive
evidence of developmental toxicity was
observed following exposure of pregnant
does to either 62.5 or 125 mg/kg/day
boric acid during the period of major
organogenesis (gd 6-19). At 250
mg/kg/day, developmental toxicity
included a high average-rate-of-resorption
(90% ofimplants per litter vs 6% for con-
trols), as well as a high percentage of does
with complete prenatal loss (73% oflitters
vs 0% for controls) (Table 4). In contrast,
the incidence oflate fetal deaths was low in
all groups (<2.8% per litter) and showed
no systematic relationship to boric acid
exposure. Average fetal bodyweight per lit-
ter was 92% that of controls at the high
dose, but this difference did not reach sta-
tistical significance. In part, the absence of
a significant fetal weight effect reflects the
small sample size for this parameter (only
six litters in the high-dose group survived
to gd 30, as compared to 18 to 23 litters in
the other studygroups).
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Table 4. Summary of maternal andembryonal/fetal responses of New Zealand rabbits to boric acid administered
on gestational days 6 to 19.
Boric acid, mg/kg/day peros)
Trend 62.5 125 250
Maternal
Total treated 23 20 22
Number removed 0 0 0
Deaths 0 0 0
Pregnancy rates, % 85 85 96
Bodyweight before treatment (gd 0 or6) -a _ _ _
Bodyweight change before treatment (gd 0-6)
Bodyweight change during treatment
(gd 6-9)
(gd 9-19) b _ _ 4
Bodyweight change aftertreatment (gd 19-30) 1 - - 4-
Bodyweight change (corrected) 4- - 4- 4-
Relative food consumption
(gd 0 to 6)




Gravid uterine weight 4- - 4
Relative liverweight
Relative kidneyweight - - - 1
Renal pathology
Embryonal/fetal
% resorptions orfetal deaths/litter I - - 1
% litters with resorptions ordeaths - - - I
% litters with 100% prenatal mortality - - - 1
Number live fetuses/litter 4- - - 4-
Average female bodyweight/litter
Average male bodyweight/litter
% malformed fetuses/litter 1 - - I





Skeletal (cardiovascular) I - - I
% fetuses with variations/litter
% litters with variations
aDashes indicate no significant change from control. bArrows indicate direction of the trend or significant change
from the control group (p<0.05).
The overall incidence of malformed
fetuses per litter was increased at 250
mg/kg/day boric acid (81% per litter vs
26% for controls), but not at 62.5 or 125
mg/kg/day (26 and 30% per litter, respec-
tively). When general classes of malforma-
tions were analyzed, the percentage of
fetuses per litter with either external or vis-
ceral malformations was increased at the
high dose, but the incidence of skeletal
malformations was comparable among
groups.
External malformations were observed
with the following incidence among indi-
vidual fetuses in the control through high-
dose groups, respectively: 0.6% (1/159),
1.1% (2/175). 0.7% (1/153), and 14.3%
(2/14). Although the overall incidence of
external malformations was increased at the
high dose of boric acid, distinctive
dose-response patterns for individual mal-
formations were not observed.
The incidence offetuses with visceral mal-
formations was 8.2% (13/159), 6.3%
(11/175), 7.8% (12/153), and 7.9%
(11/14) in the control through high-dose
groups, respectively (Table 4). Malforma-
tions of the cardiovascular (CV) system
(great vessels and heart) were the most fre-
quently observed abnormality. A post hoc
analysis of CV malformations revealed a
significant increase in the incidence of
fetuses per litter with major CV defects at
the high dose (72 vs 3% for controls). CV
malformations whose incidence appeared
to be elevated by boric acid exposure (espe-
cially at the high dose) included interven-
tricular septal defects in 0.6% of the con-
trol-group fetuses examined (1 /159), and
57% (8/14) of the high-dose fetuses; an
enlarged aorta in 0% (0/159), and 36%
(5/14) of fetuses examined in control and
high-dose groups, respectively.
The percentage offetuses with anatomi-
cal variations was not significantly elevated
above that of controls in any of the boric
acid-exposed groups.
Discussion
Three mammalian species have been evalu-
ated during gestation for developmental
toxicity of boric acid at exposure levels
which did not cause maternal mortality
(Table 5). In all three species, boric acid
was developmentally toxic to the develop-
ing embryo/fetus. In two of the species,
mice and rabbits, the developmental toxici-
ty occurred at doses which were high
enough to cause some maternal toxicity. In
rats, minimal developmental toxicity (a 6%
decrease in fetal weight) was measured at a
dosage of78 mg/kg/day in the absence of
detectable maternal toxicity. In comparing
the results of these three studies, it is
important to note that the rat and mouse
studies were feed studies, while the rabbit
study was a gavage study. Extrapolating
from the data ofTreinen and Chapin (7),
it is probable that the rodents reached
steady-state blood and tissue levels ofboric
acid by the fourth day of exposure. While
kinetic data following once-a-day gavage
studies are not available, one would expect
the profile ofblood levels to be substantial-
ly different from those of a feed study.
Thus, while some of the dose levels
(mg/kg/day) overlap, one cannot assume
comparable exposures at critical target sites.
Nonetheless, a comparison in Table 5
shows that the lowest-observed-adverse-
effect levels (LOAELs) for developmental
toxicity were 78 mg/kg/day for rats (fetal
weight reduction), 250 mg/kg/day for
rabbits (prenatal mortality and malforma-
tions) and 452 mg/kg/day for mice (fetal
weight reduction). The no-observed-
adverse-effect level (NOAELs) for develop-
mental toxicity were <78 mg/kg/day
(rats), 125 mg/kg/day (rabbits), and 248
mg/kg/day (mice). Rabbits were the
species most sensitive to boric acid-induced
prenatal mortality and malformations,
while mice were the most resistant, based
on the doses and routes of administration
employed in these studies.
Boric acid treatment of rats and mice
resulted in increased resorptions in the
presence of normal numbers of implanta-
tion sites, decreased fetal weights, and
increased numbers of malformations. The
predominant malformation in both species
was agenesis, or shortening ofthe 13th rib,
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Table 5. Comparison of results for boric acid exposure in pregnant rats, mice, and rabbits.
Dose, mg/kg/daya Maternal effects Embryonal/fetal effects
Rat, feed
78 NOAEL 4-fetal weight
163 t food intake 4-fetal weight
T liverand kidneyweights T fetuses malformed
330 1 food and water intake 4 gravid uterine weight
T liver and kidney weights 4-fetal weight
I gestational weight gain T fetuses malformed
T corrected weight gain
539 1 food and water intake 4- gravid uterine weight
T liverand kidneyweights 4-fetal weight
4-treatment weight gain T prenatal mortality
4- gestational weight gain I fetuses malformed
Mice, feed
248 1 renal lesions NOAEL
452 T renal lesions 4-fetal weight
1003 T renal lesions 4 gravid uterine weight
4 gestational weight gain 4-fetal weight
T kidneyweight T prenatal mortality




T weight gain (gd 0-30)
T corrected weight gain
T food intake (gd 25-30)
250 4 weight gain (gd 6-19) 4- gravid uterine weight
T corrected weight gain T totally resorbed litters
T relative kidneyweight 1 prenatal mortality
Tvaginal bleeding 1fetuses malformed
I food intake (gd 6-15)
T food intake (gd 25-30)
a The following routes and periods of exposure were used: rats (0.1, 0.2, 0.4% in feed on gd 0-20; 0.8% in feed on
gd 6-15); mice (0.1, 0.2, 0.4% in feed on gd 0-17); rabbits by gavage 5 ml/kg on gd 6-19.
which occurred in the presence of reduced
fetal weight and maternal toxicity. The
increase in the number of enlarged lateral
ventricles ofthe brain, as well as an increase
in the number ofwavy ribs (variation), was
observed in rats, but these anomalies were
observed in the presence ofsevere decreases
in fetal weight. Indeed, decreases in fetal
body weight comparable to those observed
in the boric acid study have been reported
following exposure of CD rats to carba-
mazepine on gd 7 to 18 (21). Average fetal
body weights were 80, 57, and 48% that of
control weights for 200, 400, or 600
mg/kg/day carbamazepine, respectively,
but fetuses evaluated by Wilson's method
(17) on gd 20 were not reported to have
enlarged lateral ventricles or other related
central nervous system malformations. This
suggests that ventricular enlargement in gd
20 rat fetuses following boric acid exposure
is not simply a secondary expression of
growth retardation.
However, only 5% of the rat fetuses
showed the enlarged lateral ventricles.
Further studies (unpublished) have shown
that the enlarged lateral ventricles were not
produced when boric acid was dosed dur-
ing only one of the sensitive periods for
induction of brain malformations (i.e., gd
14-17) suggesting that the effect of boric
acid on lateral ventricles occurs before gd
14. In contrast, the rabbit's cardiovascular
system was clearly a target for boric acid
exposure, since 72% of fetuses/litter (250
mg/kg/day) had at least one major car-
diovascular malformation, compared to
only 3% for controls.
Susceptibility to boric acid-induced
prenatal mortality of the conceptus
showed major differences across species
despite comparable control values (4-6%
of implants resorbed/litter). Rabbits were
not only most sensitive to this effect, but
were also the most severely affected
species, experiencing 90% resorptions/lit-
ter at 250 mg/kg/day (gd 6-19). The
extent of prenatal mortality in rats
depended upon both the daily dose and
the period ofadministration. Rats showed
36 or 76% resorptions, respectively, at
539 mg/kg/day (gd 6-15) (14), or at
617 mg/kg/day (gd 0-20) (NTP pilot
study). In contrast, mice were relatively
resistant to such effects, and showed only
20% resorptions/litter after exposure to
1003 mg/kg/day throughout gestation
(gd 0-17) (15).
With regard to maternal toxicity, the
rat was the most sensitive (163
mg/kg/day), while both the mouse and
rabbit showed maternal toxicity at 250
mg/kg/day. Kidney weight was increased
in all three species, but histologic kidney
lesions were detected only in the mouse
study. Indeed, on the basis of kidney his-
tology the maternal NOAEL was less than
248 mg/kg/day.
Conclusion
In summary, boric acid caused develop-
mental toxicity in three species: rat,
mouse, and rabbit. Developmental toxici-
ty occurs with doses of boric acid in the
range of 80 to 400 mg/kg/day, given
either throughout gestation or only dur-
ing major organogenesis. Developmental
toxicity manifests as decreased fetal body
weight and increased malformations; pre-
natal death, depending on the dose and
species, usually occurs in the presence of
maternal toxicity. These data must be
interpreted with respect to the level of
human exposure and sensitivity in order
assess potential risk to human health. In
this regard, recent studies have shown that
the highest exposures to boron achieved as
a result of dietary intake plus worker
exposure were 0.38 mg boron/kg/day or
approximately 1.9 mg/kg/day of boric
acid (22).
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